About US
Contact us
-
Government still has 'no settlement' with Mylan, CMS administrator saysLast fall, Mylan announced it had reached a swift settlement with the U.S. Department of Justice over allegedMedicaid misclassifications on thebig-selling EpiPen. But now, a top U.S. health official s2017/2/14
-
Is Praluent doomed? Regeneron, Sanofi appeal for a reprieve, but experts are skepticalSanofi and Regeneron have made their bid for a Praluent reprieve. In the wake of a district judge’s patent ruling that could push the partners’ new cholesterol drug off the market, the two companies a2017/2/14
-
Supreme Court takes up Amgen, Sandoz's market-defining biosimilars disputeThe U.S. Supreme Court will take on a closely watched legal skirmish between Amgen and Novartis’ Sandoz, with the outcome set to define launch timelines across the budding biosim field. The Supreme2017/2/13
-
Biogen to fork over $1.25B-plus to settle blockbuster Tecfidera patent fight with ForwardBiogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash. And if Forward wins particular patent rights on its rival drug, Biogen will be on the ho2017/2/13
-
Eli Lilly's Alimta escapes early generics—and a sales hit—with patent win over TevaChalk up a win for Eli Lilly in a much-watched patent tussle over the blockbuster cancer med Alimta. A federal appeals court said generic versions from Teva and others would step on a key Lilly patent2017/2/10
-
Amid insulin market scrutiny, Novo faces class action alleging 'collusive price fixing'While all of biopharma felt the sting of tough talk from President-elect Donald Trump on Wednesday, Novo Nordisk faced some fresh concerns of its own. A New York law firm said it filed aclass actionsu2017/2/10
-
Regeneron CEO: Amgen's disruptive Praluent-blocking patent move hurts patientsSAN FRANCISCO—Last week, a U.S. District Courtblocked salesof Sanofi and Regeneron’s PCSK9 med, Praluent, as part of an ongoing patent war with Repatha-maker Amgen. And Monday at the J.P. Morgan Healt2017/2/9
-
J&J and Actelion reportedly take complicated deal to Swiss regulator for rulingThere is evidence that Actelion and Johnson & Johnson are edging closerto a deal to give the U.S. drugmaker control of the Swiss biotech, sort of. Citing a report in the Swiss newspaper Tages-Anz2017/2/9
-
Sanofi and Regeneron ordered to halt Praluent sales, but companies to appeal judge's decisionA U.S. federal judge handed Sanofi and partner Regeneron a stunning loss with a ban on sales of their cholesterol-lowering drug Praluent in the U.S. after a jury said it infringed Amgen’s patent for r2017/2/8
-
Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent rulingAmgen has been in a tight race with Sanofi and Regeneron to win market acceptance for a new class of drugs that fight ultra-high cholesterol by inhibiting an enzyme called PCSK9—a fight that includes2017/2/8